Jonathan Rigby, BioPlus Acquisition Corp board chair and CBO
Even as boom wanes, a new $200M SPAC is still hoping for another big score
The biotech sector has been booming throughout the Covid-19 pandemic — and while it has slowed down considerably, there are yet more SPACs at work. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
